PTC Therapeutics PTCT Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's royalty — revenue?
- PTC Therapeutics (PTCT) reported royalty — revenue of $46.84M in Q1 2026.
- How has PTC Therapeutics's royalty — revenue changed year-over-year?
- PTC Therapeutics's royalty — revenue increased by 28.5% year-over-year, from $36.44M to $46.84M.
- What is the long-term trend for PTC Therapeutics's royalty — revenue?
- Over 4 years (2021 to 2025), PTC Therapeutics's royalty — revenue has grown at a 45.3% compound annual growth rate (CAGR), from $54.72M to $244.23M.
- What does royalty — revenue mean?
- This metric represents the gross revenue recognized from royalty-based licensing agreements for intellectual property, excluding any pass-through taxes collected from customers. It reflects the income generated from the commercial success of products developed by the company but marketed or sold by third-party partners. This figure serves as a key indicator of the company's ability to monetize its research and development pipeline through strategic licensing and partnership models.